Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie pembrolizumabu (MK-3475) v kombinaci s adjuvantní chemoterapií s radioterapií nebo bez ní u účastníků s nově diagnostikovaným karcinomem endometria po operaci s kurativním záměrem (MK-3475-B21 / KEYNOTE-B21 / ENGOT-cs11 / GOG-3053)

17. září 2026 aktualizováno: Merck Sharp & Dohme LLC

Randomizovaná, dvojitě zaslepená studie fáze 3 Pembrolizumab versus placebo v kombinaci s adjuvantní chemoterapií s radioterapií nebo bez ní pro léčbu nově diagnostikovaného vysoce rizikového karcinomu endometria po operaci s kurativním záměrem (KEYNOTE-B21 / ENGOT-cs11 / GOG- 3053)

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.

Přehled studie

Typ studie

Intervenční

Zápis (Odhadovaný)

990

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Buenos Aires, Argentina, C1012AAR
        • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
      • Buenos Aires, Argentina, C1118AAT
        • Hospital Aleman ( Site 1001)
      • La Rioja, Argentina, F5300COE
        • Centro Oncologico Riojano Integral ( Site 1007)
    • Buenos Aires
      • Berazategui, Buenos Aires, Argentina, B1884BBF
        • Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
      • CABA, Buenos Aires, Argentina, C1012AAR
        • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
      • CABA, Buenos Aires, Argentina, C1431FWO
        • CEMIC ( Site 1009)
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB
        • Hospital Britanico de Buenos Aires ( Site 1002)
      • Mar del Plata, Buenos Aires, Argentina, B7600FZO
        • Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000KZE
        • Instituto de Oncologia de Rosario ( Site 1004)
      • Liège, Belgie, 4000
        • CHC - Groupe Sante ( Site 2041)
      • Liège, Belgie, 4000
        • CHU Liege Sart-Tilman ( Site 2044)
    • Bruxelles-Capitale, Region de
      • Brussels, Bruxelles-Capitale, Region de, Belgie, 1200
        • Saint-Luc UCL ( Site 2042)
    • Hainaut
      • Mons, Hainaut, Belgie, 7000
        • C.I.U. Hopital Ambroise Pare ( Site 2039)
    • Liege
      • Verviers, Liege, Belgie, 4800
        • CHR Verviers ( Site 2035)
    • Oost-Vlaanderen
      • Aalst, Oost-Vlaanderen, Belgie, 9300
        • AZORG Campus Aalst-Moorselbaan ( Site 2038)
      • Ghent, Oost-Vlaanderen, Belgie, 9000
        • AZ Maria Middelares Gent ( Site 2032)
      • Ghent, Oost-Vlaanderen, Belgie, 9000
        • Universitair Ziekenhuis Gent ( Site 2037)
      • Sint-Niklaas, Oost-Vlaanderen, Belgie, 9100
        • AZ Nikolaas ( Site 2031)
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgie, 3000
        • UZ Leuven ( Site 2040)
    • West-Vlaanderen
      • Kortrijk, West-Vlaanderen, Belgie, 8500
        • AZ Groeninge ( Site 2036)
    • Araucania
      • Temuco, Araucania, Chile, 4800827
        • Centro Investigación del Cáncer James Lind ( Site 1061)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Fundacion Arturo Lopez Perez FALP ( Site 1062)
      • Santiago, Region M. de Santiago, Chile, 8330032
        • Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063)
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 1070)
    • Valparaiso
      • Viña del Mar, Valparaiso, Chile, 2520598
        • Oncocentro ( Site 1065)
    • Capital Region
      • Copehagen, Capital Region, Dánsko, 2100
        • Rigshospitalet University Hospital ( Site 2515)
      • Herlev, Capital Region, Dánsko, 2730
        • Herlev Hospital ( Site 2514)
    • North Denmark
      • Aalborg, North Denmark, Dánsko, 9100
        • Aalborg Universitetshospital ( Site 2511)
    • Region Sjælland
      • Roskilde, Region Sjælland, Dánsko, 4000
        • Roskilde Sygehus ( Site 2513)
    • Region Syddanmark
      • Odense, Region Syddanmark, Dánsko, 5000
        • Odense Universitetshospital ( Site 2512)
    • Northern Savonia
      • Kuopio, Northern Savonia, Finsko, 70210
        • Kuopio University Hospital ( Site 2543)
    • Pirkanmaa
      • Tampere, Pirkanmaa, Finsko, 33520
        • Tampere University Hospital ( Site 2541)
    • Southwest Finland
      • Turku, Southwest Finland, Finsko, 20520
        • Turku University Hospital ( Site 2542)
    • Ain
      • Vandœuvre-lès-Nancy, Ain, Francie, 54519
        • Institut De Cancerologie De Lorraine ( Site 2072)
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Francie, 06189
        • Centre Antoine Lacassagne ( Site 2073)
    • Calvados
      • Caen, Calvados, Francie, 14076
        • Centre Francois Baclesse ( Site 2062)
    • Cotes-d Armor
      • Plérin, Cotes-d Armor, Francie, 22190
        • Hôpital Privé Des Côtes d'Armor ( Site 2063)
    • Doubs
      • Besançon, Doubs, Francie, 25000
        • CHU Besancon - Hopital Jean Minjoz ( Site 2068)
    • Gironde
      • Bordeaux, Gironde, Francie, 33076
        • Institut Bergonie ( Site 2067)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, Francie, 31059
        • Institut Universitaire du Cancer Toulouse - Oncopole ( Site 2065)
    • Herault
      • Montpellier, Herault, Francie, 34298
        • Institut Regional du Cancer de Montpellier - ICM ( Site 2069)
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, Francie, 44277
        • Hopital prive du Confluent ( Site 2061)
    • Rhone
      • Pierre-Bénite, Rhone, Francie, 69310
        • Centre Hospitalier Lyon Sud ( Site 2064)
    • Île-de-France Region
      • Paris, Île-de-France Region, Francie, 75014
        • Hopital Cochin ( Site 2070)
      • Villejuif, Île-de-France Region, Francie, 94805
        • Gustave Roussy ( Site 2071)
      • Brescia, Itálie, 25123
        • Azienda Ospedaliera Spedali Civili di Brescia ( Site 2135)
      • Milan, Itálie, 20132
        • IRCCS Ospedale San Raffaele ( Site 2130)
      • Milan, Itálie, 20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 2132)
      • Naples, Itálie, 80131
        • Azienda Ospedaliera Universitaria Federico II ( Site 2123)
      • Naples, Itálie, 80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2127)
      • Padova, Itálie, 35128
        • Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 2134)
    • Abruzzo
      • Roma, Abruzzo, Itálie, 00144
        • Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 2121)
    • Lazio
      • Rome, Lazio, Itálie, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli ( Site 2124)
    • Lombardy
      • Milan, Lombardy, Itálie, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2122)
    • Piedmont
      • Candiolo, Piedmont, Itálie, 10060
        • INOC - Istituto Nazionale Oncologico Candiolo ( Site 2125)
      • Haifa, Izrael, 3525408
        • Rambam Medical Center ( Site 2307)
      • Holon, Izrael, 5810001
        • Edith Wolfson Medical Center ( Site 2306)
      • Jerusalem, Izrael, 9112001
        • Hadassah Medical Center. Ein Kerem ( Site 2303)
      • Petah Tikva, Izrael, 4941492
        • Rabin Medical Center ( Site 2305)
      • Ramat Gan, Izrael, 5265601
        • Chaim Sheba Medical Center ( Site 2301)
      • Fukuoka, Japonsko, 811-1395
        • National Hospital Organization Kyushu Cancer Center ( Site 4193)
      • Niigata, Japonsko, 951-8566
        • Niigata Cancer Center Hospital ( Site 4185)
      • Osaka, Japonsko, 541-8567
        • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 4188)
      • Tokyo, Japonsko, 160-8582
        • Keio University Hospital ( Site 4191)
      • Tokyo, Japonsko, 135-8550
        • Cancer Institute Hospital of JFCR ( Site 4196)
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonsko, 464-8681
        • Aichi Cancer Center ( Site 4190)
    • Chiba
      • Kashiwa, Chiba, Japonsko, 277-8577
        • National Cancer Center Hospital East ( Site 4197)
    • Ehime
      • Matsuyama, Ehime, Japonsko, 791-0280
        • National Hospital Organization Shikoku Cancer Center ( Site 4181)
      • Tōon, Ehime, Japonsko, 791-0295
        • Ehime University Hospital ( Site 4187)
    • Fukuoka
      • Kurume, Fukuoka, Japonsko, 830-0011
        • Kurume University Hospital ( Site 4186)
    • Gunma
      • Ōta, Gunma, Japonsko, 373-8550
        • Gunma Prefectural Cancer Center ( Site 4183)
    • Hokkaido
      • Sapporo, Hokkaido, Japonsko, 060-8648
        • Hokkaido University Hospital ( Site 4194)
    • Hyōgo
      • Akashi, Hyōgo, Japonsko, 673-8558
        • Hyogo Cancer Center ( Site 4195)
    • Iwate
      • Shiwa-gun, Iwate, Japonsko, 028-3695
        • Iwate Medical University Hospital ( Site 4189)
    • Okinawa
      • Ginowan, Okinawa, Japonsko, 901-2725
        • University of the Ryukyus Hospital ( Site 4184)
    • Saitama
      • Hidaka, Saitama, Japonsko, 350-1298
        • Saitama Medical University International Medical Center ( Site 4182)
    • Shizuoka
      • Suntogun, Shizuoka, Japonsko, 411-8777
        • Shizuoka Cancer Center ( Site 4192)
      • Seoul, Jižní Korea, 03722
        • Severance Hospital Yonsei University Health System ( Site 4062)
      • Seoul, Jižní Korea, 05505
        • Asan Medical Center ( Site 4061)
      • Seoul, Jižní Korea, 06351
        • Samsung Medical Center ( Site 4064)
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Jižní Korea, 10408
        • National Cancer Center ( Site 4065)
      • Seongnam-si, Kyonggi-do, Jižní Korea, 13620
        • Seoul National University Bundang Hospital ( Site 4063)
    • Alberta
      • Calgary, Alberta, Kanada, T2N 5G2
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 3007)
    • Ontario
      • Kingston, Ontario, Kanada, K7L 2V7
        • Kingston Health Sciences Centre ( Site 3003)
    • Quebec
      • Montreal, Quebec, Kanada, H2X 0C1
        • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 3006)
      • Montreal, Quebec, Kanada, H4A 3J1
        • McGill University Health Centre ( Site 3005)
      • Québec, Quebec, Kanada, G1J 1Z4
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 3002)
    • Antioquia
      • Medellín, Antioquia, Kolumbie, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1096)
    • Bogota D.C.
      • Bogotá, Bogota D.C., Kolumbie, 111511
        • Instituto Nacional de Cancerología E.S.E ( Site 1094)
    • Departamento de Nariño
      • Pasto, Departamento de Nariño, Kolumbie, 520002
        • Instituto Cancerologico de Nariño S.A.S. ( Site 1092)
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Kolumbie, 760032
        • Fundación Valle del Lili ( Site 1093)
      • Mexico City, Mexiko, 06700
        • Hospital Angeles Roma ( Site 1123)
    • Baja California Sur
      • La Paz, Baja California Sur, Mexiko, 23040
        • Investigacion Onco Farmaceutica S de RL de CV ( Site 1127)
    • Chiapas
      • Tuxtla Gutiérrez, Chiapas, Mexiko, 29090
        • Hospital San Lucas Cardiologica del Sureste ( Site 1122)
    • Mexico City
      • Mexico City, Mexico City, Mexiko, 04700
        • Centro Oncologico Internacional. SEDNA ( Site 1121)
      • Mexico City, Mexico City, Mexiko, 14080
        • Instituto Nacional de Cancerologia ( Site 1124)
    • Nuevo León
      • Monterrey, Nuevo León, Mexiko, 64460
        • Filios Alta Medicina ( Site 1125)
      • Monterrey, Nuevo León, Mexiko, 64710
        • I Can Oncology Center SA de CV ( Site 1126)
      • Oslo, Norsko, 0310
        • Oslo Universitetssykehus Radiumhospitalet ( Site 2151)
    • Troms
      • Tromsø, Troms, Norsko, 9019
        • University Hospital of North Norway ( Site 2153)
    • Vest-Agder
      • Kristiansand, Vest-Agder, Norsko, 4615
        • Soerlandet sykehus HF Kristiansand ( Site 2152)
    • Baden-Wurttemberg
      • Heilbronn, Baden-Wurttemberg, Německo, 74078
        • SLK-Kliniken Heilbronn GmbH ( Site 2116)
      • Ludwigsburg, Baden-Wurttemberg, Německo, 71640
        • Klinikum Ludwigsburg ( Site 2111)
      • Tübingen, Baden-Wurttemberg, Německo, 72076
        • Universitaetsklinikum Tuebingen ( Site 2113)
    • Lower Saxony
      • Hanover, Lower Saxony, Německo, 30625
        • Medizinische Hochschule Hannover-Department of Obstetrics and Gynecology ( Site 2109)
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Německo, 53127
        • Universitätsklinikum Bonn-Gynaecological oncology ( Site 2103)
      • Essen, North Rhine-Westphalia, Německo, 45136
        • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 2105)
    • Saxony
      • Dresden, Saxony, Německo, 01307
        • Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur ( Site 2104)
    • Schleswig-Holstein
      • Lübeck, Schleswig-Holstein, Německo, 23538
        • Universitätsklinikum Schleswig-Holstein ( Site 2101)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polsko, 61-866
        • Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
    • Masovian Voivodeship
      • Siedlce, Masovian Voivodeship, Polsko, 08-110
        • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2487)
      • Warsaw, Masovian Voivodeship, Polsko, 00-315
        • Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 2481)
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polsko, 15-027
        • Bialostockie Centrum Onkologii ( Site 2483)
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Polsko, 44-102
        • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2482)
    • Warmian-Masurian Voivodeship
      • Olsztyn, Warmian-Masurian Voivodeship, Polsko, 10-228
        • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2486)
    • Świętokrzyskie Voivodeship
      • Kielce, Świętokrzyskie Voivodeship, Polsko, 25-734
        • Swietokrzyskie Centrum Onkologii. ( Site 2485)
    • Styria
      • Graz, Styria, Rakousko, 8036
        • Medizinische Universitat Graz ( Site 2004)
    • Tyrol
      • Innsbruck, Tyrol, Rakousko, 6020
        • Medizinische Universitaet Innsbruck ( Site 2001)
    • Arkhangelskaya oblast
      • Arkhangelsk, Arkhangelskaya oblast, Rusko, 163045
        • Arkhangelsk Clinical Oncological Dispensary ( Site 2637)
    • Baskortostan, Respublika
      • Ufa, Baskortostan, Respublika, Rusko, 450054
        • Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 2645)
    • Chelyabinsk Oblast
      • Chelyabinsk, Chelyabinsk Oblast, Rusko, 454087
        • Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
    • Krasnoyarsk Krai
      • Krasnoyarsk, Krasnoyarsk Krai, Rusko, 660133
        • Krasnoyarsk Regional Clinical oncology dispensary ( Site 2643)
    • Mordoviya, Respublika
      • Saransk, Mordoviya, Respublika, Rusko, 430032
        • National Research Ogarev Mordovia State University ( Site 2648)
    • Moscow
      • Moscow, Moscow, Rusko, 115522
        • Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF Dep.of antitumor drug therapy #4 ( Site 2634)
      • Moscow, Moscow, Rusko, 125284
        • Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2631)
    • Nizhny Novgorod Oblast
      • Nizhny Novgorod, Nizhny Novgorod Oblast, Rusko, 603126
        • Scientific Research Institute of Clinical Oncology "Nizhegorodsky Regional Oncology Dospensary" ( Site 2639)
    • Samara Oblast
      • Samara, Samara Oblast, Rusko, 443031
        • Samara Regional Clinical Oncology Center-Chemotherapy Dapartment ( Site 2649)
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Rusko, 197758
        • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2636)
    • Tatarstan, Respublika
      • Kazan', Tatarstan, Respublika, Rusko, 420029
        • Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2646)
    • Tomsk Oblast
      • Tomsk, Tomsk Oblast, Rusko, 634028
        • Tomsk Scientific Research Institute of Oncology-Chemotherapy ( Site 2638)
    • Yaroslavl Oblast
      • Yaroslavl, Yaroslavl Oblast, Rusko, 150054
        • Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 2641)
      • Leicester, Spojené království, LE1 5WW
        • Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 2249)
      • Manchester, Spojené království, M20 4BX
        • The Christie Hospital NHS Foundation Trust ( Site 2243)
    • Bristol, City of
      • Bristol, Bristol, City of, Spojené království, BS2 8ED
        • Bristol Haematology and Oncology Centre ( Site 2244)
    • East Riding Of Yorkshire
      • Cottingham, East Riding Of Yorkshire, Spojené království, HU165JQ
        • Castle Hill Hospital-Academic Oncology ( Site 2252)
    • Glasgow City
      • Glasgow, Glasgow City, Spojené království, G12 0YN
        • Beatson West of Scotland Cancer Centre ( Site 2247)
    • London, City of
      • London, London, City of, Spojené království, NW1 2PG
        • UCLH NHS Foundation Trust ( Site 2242)
      • London, London, City of, Spojené království, SW3 6JJ
        • Royal Marsden NHS Foundation Trust ( Site 2248)
      • Sutton, London, City of, Spojené království, SM2 5PT
        • Royal Marsden Hospital Sutton-Surrey ( Site 2241)
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35249
        • University of Alabama - Birmingham ( Site 3061)
      • Mobile, Alabama, Spojené státy, 36604
        • University of South Alabama, Mitchell Cancer Institute ( Site 3058)
    • Arizona
      • Phoenix, Arizona, Spojené státy, 85016
        • HonorHealth Research Institute - Biltmore ( Site 3043)
      • Tucson, Arizona, Spojené státy, 85711
        • Arizona Oncology Associates PC- HOPE ( Site 3049)
    • California
      • La Jolla, California, Spojené státy, 92093-0698
        • UCSD Moores Cancer Center ( Site 3053)
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • University Of Colorado ( Site 3051)
    • Connecticut
      • New Haven, Connecticut, Spojené státy, 06511
        • Smilow Cancer Hospital at Yale New Haven ( Site 3070)
    • Florida
      • Miami Beach, Florida, Spojené státy, 33140
        • Mount Sinai Cancer Center ( Site 3081)
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30342
        • Northside Hospital ( Site 3036)
    • Illinois
      • Chicago, Illinois, Spojené státy, 60611
        • Northwestern Memorial Hospital ( Site 3044)
    • Indiana
      • Fort Wayne, Indiana, Spojené státy, 46845
        • Parkview Cancer Institute ( Site 3067)
      • Indianapolis, Indiana, Spojené státy, 46202
        • Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
    • Iowa
      • Iowa City, Iowa, Spojené státy, 52242
        • University of Iowa Hospital and Clinics ( Site 3046)
    • Kentucky
      • Louisville, Kentucky, Spojené státy, 40207
        • Norton Cancer Institute - St. Matthews ( Site 3056)
    • Louisiana
      • Shreveport, Louisiana, Spojené státy, 71103
        • WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
    • Massachusetts
      • Worcester, Massachusetts, Spojené státy, 01605
        • University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
    • New York
      • Mineola, New York, Spojené státy, 11501
        • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
      • New York, New York, Spojené státy, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
      • The Bronx, New York, Spojené státy, 10461
        • Montefiore Medical Center ( Site 3065)
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27710
        • Duke Cancer Center ( Site 3072)
    • North Dakota
      • Fargo, North Dakota, Spojené státy, 58102
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
    • Ohio
      • Columbus, Ohio, Spojené státy, 43210
        • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
    • Oregon
      • Portland, Oregon, Spojené státy, 97210
        • Legacy Good Samaritan Medical Center ( Site 3033)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19107
        • Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
      • Pittsburgh, Pennsylvania, Spojené státy, 15224
        • AHN West Penn Hospital ( Site 3060)
      • Willow Grove, Pennsylvania, Spojené státy, 19090
        • Abington Hospital - Asplundh Cancer Center ( Site 3073)
    • South Dakota
      • Sioux Falls, South Dakota, Spojené státy, 57104
        • Sanford Gynecology Oncology ( Site 3045)
    • Texas
      • Dallas, Texas, Spojené státy, 75390
        • UT Southwestern Medical Center ( Site 3063)
    • Virginia
      • Richmond, Virginia, Spojené státy, 23298
        • VCU Massey Cancer Center ( Site 3068)
      • Changhua, Tchaj-wan, 50006
        • Changhua Christian Hospital ( Site 4095)
      • Taichung, Tchaj-wan, 407
        • Taichung Veterans General Hospital ( Site 4094)
      • Taipei, Tchaj-wan, 10449
        • MacKay Memorial Hospital ( Site 4092)
      • Taipei, Tchaj-wan, 11217
        • Taipei Veterans General Hospital ( Site 4093)
      • Taoyuan, Tchaj-wan, 33305
        • Linkou Chang Gung Memorial Hospital ( Site 4091)
      • Adana, Turecko (Türkiye), 01250
        • Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2355)
      • Adana, Turecko (Türkiye), 01330
        • Cukurova Uni. Tip Fakultesi ( Site 2353)
      • Ankara, Turecko (Türkiye), 06490
        • Baskent Universitesi Ankara Hastanesi ( Site 2354)
      • Ankara, Turecko (Türkiye), 06590
        • Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 2350)
      • Istanbul, Turecko (Türkiye), 34214
        • Medipol Universite Hastanesi ( Site 2352)
      • Izmir, Turecko (Türkiye), 35100
        • Ege University Medical Faculty ( Site 2351)
      • Izmir, Turecko (Türkiye), 35575
        • I.E.U. Medical Point Hastanesi ( Site 2356)
    • Chernihiv Oblast
      • Chernihiv, Chernihiv Oblast, Ukrajina, 14029
        • Chernihiv Medical Center of Modern Oncology ( Site 2368)
    • Chernivetska Oblast
      • Chernivtsi, Chernivetska Oblast, Ukrajina, 58013
        • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 2366)
    • Kharkiv Oblast
      • Kharkiv, Kharkiv Oblast, Ukrajina, 61024
        • SO Grigoriev Institute for Medical Radiology and Oncology of NAMS of Ukraine ( Site 2363)
    • Khmelnytskyi Oblast
      • Khmelnitskyi, Khmelnytskyi Oblast, Ukrajina, 29009
        • MNE "Khmelnytskyi regional antitumor center" ( Site 2365)
    • Kyivska Oblast
      • Kiev, Kyivska Oblast, Ukrajina, 08720
        • LISOD - Israeli Oncological Hospital MedX-ray International Group LLC ( Site 2364)
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukrajina, 79031
        • Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2361)
    • Volyn Oblast
      • Lutsk, Volyn Oblast, Ukrajina, 43018
        • Volyn Regional Clinical Hospital Regional Medical Oncology Centre ( Site 2362)
      • Olomouc, Česko, 77900
        • Fakultni nemocnice Olomouc ( Site 2392)
    • Brno-mesto
      • Brno, Brno-mesto, Česko, 62500
        • Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 2394)
    • Praha 10
      • Prague, Praha 10, Česko, 100 34
        • Fakultni nemocnice Kralovske Vinohrady ( Site 2393)
    • Praha 2
      • Prague, Praha 2, Česko, 128 08
        • Vseobecna fakultni nemocnice v Praze ( Site 2391)
    • Anhui
      • Hefei, Anhui, Čína, 230001
        • Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 4034)
    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100036
        • Beijing Cancer Hospital ( Site 4048)
      • Beijing, Beijing Municipality, Čína, 100730
        • Peking Union Medical College Hospital ( Site 4036)
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Čína, 400030
        • Chongqing Cancer Hospital ( Site 4040)
    • Fujian
      • Xiamen, Fujian, Čína, 361003
        • The First Affiliated Hospital of Xiamen University ( Site 4060)
    • Guangdong
      • Guangzhou, Guangdong, Čína, 510080
        • The First Affiliated Hospital ( Site 4043)
    • Guangxi
      • Nanning, Guangxi, Čína, 530221
        • Guangxi Medical University Affiliated Tumor Hospital ( Site 4049)
    • Heilongjiang
      • Harbin, Heilongjiang, Čína, 150081
        • Harbin Medical University Cancer Hospital ( Site 4033)
    • Hubei
      • Wuhan, Hubei, Čína, 430079
        • Hubei Cancer Hospital ( Site 4059)
    • Hunan
      • Changsha, Hunan, Čína, 410006
        • Hunan Cancer Hospital ( Site 4050)
      • Changsha, Hunan, Čína, 410008
        • Xiangya Hospital Central South University ( Site 4035)
    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210008
        • Nanjing Drum Tower Hospital ( Site 4037)
    • Jiangxi
      • Nanchang, Jiangxi, Čína, 530021
        • Jiangxi Maternal and Child Health Hospital ( Site 4051)
    • Jilin
      • Changchun, Jilin, Čína, 130000
        • The First Hospital of Jilin University ( Site 4057)
    • Shaanxi
      • Xi'an, Shaanxi, Čína, 710061
        • The First Affiliated Hospital of Xi an Jiaotong University ( Site 4045)
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Čína, 200090
        • Obstetrics and Gynecology Hosp. Fudan University ( Site 4041)
      • Shanghai, Shanghai Municipality, Čína, 200127
        • Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 4053)
      • Shanghai, Shanghai Municipality, Čína, 201204
        • Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 4001)
    • Sichuan
      • Chengdu, Sichuan, Čína, 610041
        • Sichuan Cancer Hospital. ( Site 4039)
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Čína, 300000
        • Tianjin Medical University Cancer Institute & Hospital ( Site 4054)
    • Yunnan
      • Kunming, Yunnan, Čína, 650107
        • Yunnan Province Cancer Hospital-Gynecology Department ( Site 4055)
    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 310003
        • The First Affiliated Hospital, Zhejiang University-Gynecology ( Site 4002)
      • Hangzhou, Zhejiang, Čína, 310006
        • Women s Hospital School of Medicine Zhejiang University ( Site 4032)
      • Wenzhou, Zhejiang, Čína, 325000
        • The First Affiliated Hospital of Wenzhou Medical University ( Site 4056)
      • Thessaloniki, Řecko, 546 45
        • Euromedica General Clinic of Thessaloniki ( Site 2422)
    • Achaia
      • Pátrai, Achaia, Řecko, 263 35
        • General Hospital of Patras. St Andrews ( Site 2421)
    • Attica
      • Athens, Attica, Řecko, 115 28
        • Geniko Panepistimako Nosokomeio ARETEIO ( Site 2423)
      • Athens, Attica, Řecko, 115 28
        • Perifereiako Geniko Nosokomeio ALEXANDRA ( Site 2425)
      • Chaïdári, Attica, Řecko, 124 62
        • Athens University Hospital ATTIKON ( Site 2424)
      • Marousi, Attica, Řecko, 151 23
        • Hospital Hygeia ( Site 2426)
      • Barcelona, Španělsko, 08035
        • Hospital Vall D Hebron ( Site 2182)
      • Barcelona, Španělsko, 08036
        • Hospital Clinic i Provincial ( Site 2185)
      • Córdoba, Španělsko, 14004
        • Hospital Universitario Reina Sofia ( Site 2183)
      • Madrid, Španělsko, 28040
        • Hospital Clinico San Carlos ( Site 2187)
      • Madrid, Španělsko, 28046
        • Hospital Universitario La Paz ( Site 2186)
    • Gerona
      • Girona, Gerona, Španělsko, 17007
        • Institut Català d'Oncologia (ICO) - Girona ( Site 2184)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Španělsko, 28027
        • Clinica Universitaria de Navarra ( Site 2181)
    • Stockholm County
      • Solna, Stockholm County, Švédsko, 171 76
        • Karolinska Universitetssjukhuset Solna ( Site 2220)
    • Uppsala County
      • Uppsala, Uppsala County, Švédsko, 751 85
        • Blod-och Tumorsjukdomar ( Site 2221)
    • Östergötland County
      • Linköping, Östergötland County, Švédsko, 581 85
        • Universitetssjukhuset i Linkoping. ( Site 2222)

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor) and:

    • Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy; and
    • Is at high risk for recurrence following treatment with curative intent surgery, ie: Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2009 surgical stage I/II with myometrial invasion of non-endometrioid histology; FIGO 2009 surgical stage I/II with myometrial invasion of any histology with known aberrant p53 expression or p53 mutation; or FIGO (2009) surgical stage III or IVA of any histology.
  • Is disease-free with no evidence of loco-regional disease or distant metastasis post operatively and on imaging.

  • Has not received any radiation or systemic therapy, including immunotherapy, hormonal therapy, or hyperthermic intraperitoneal chemotherapy (HIPEC), in any setting including the neoadjuvant setting for endometrial cancer (EC).

  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.

  • Submission of a tumor tissue sample from current diagnosis of Endometrial Carcinoma or Carcinosarcoma for prospective determination of histology and mismatch repair (MMR) status by central vendor is required for all participants.

  • Has adequate organ function within 7 days of randomization.

Exclusion Criteria:

  • Has recurrent endometrial carcinoma or carcinosarcoma.

  • Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.

  • Has FIGO (2009) Surgical Stage I/II EC of endometrioid histology without a known aberrant p53 expression or p53 mutation.

  • Is known to have a deoxyribonucleic acid (DNA) polymerase epsilon catalytic subunit A (POLE) mutation.

  • Has FIGO Stage IVB disease of any histology even if there is no evidence of disease after surgery.

  • Has residual tumor whether measurable or non-measurable after surgery.

  • Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.

    • Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.
  • Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).

  • Has received a live vaccine within 30 days before the first dose of study intervention.

    • Note: killed vaccines are allowed.
  • Has a known intolerance to study intervention (or any of the excipients).

  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.

    • Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
  • Has any contraindication to the use of carboplatin or paclitaxel.

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.

  • Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

  • Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.

  • Has an active infection requiring systemic therapy.

  • Has a known history of HIV infection.

  • Has a known history of Hepatitis B or known active Hepatitis C virus infection.

  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

  • Has had an allogenic tissue/solid organ transplant.

  • Has not recovered adequately from surgery and/or any complications from the surgery.

  • Is breastfeeding.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Pembrolizumab + Chemotherapy

Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.

IV infusion

Ostatní jména:
  • MK-3475
  • KEYTRUDA®

IV infusion

IV infusion

IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

Ostatní jména:
  • Platinol®
  • Platinol®-AQ

≥4500 cGY given according to local practice, at the discretion of the investigator

If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

Ostatní jména:
  • Platinol®
  • Platinol®-AQ

Given according to local practice, at the discretion of the investigator

Ostatní jména:
  • Vnitřní radiační terapie
Komparátor placeba: Placebo + Chemotherapy

Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.

IV infusion

IV infusion

IV infusion docetaxel 75 mg/m^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Cisplatin 75 mg/m^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

Ostatní jména:
  • Platinol®
  • Platinol®-AQ

≥4500 cGY given according to local practice, at the discretion of the investigator

If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

Ostatní jména:
  • Platinol®
  • Platinol®-AQ

Given according to local practice, at the discretion of the investigator

Ostatní jména:
  • Vnitřní radiační terapie

IV infusion

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence
Časové okno: Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence, will be presented.

Up to approximately 42 months
Overall Survival (OS)
Časové okno: Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause.

Up to approximately 54 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Disease-Free Survival (DFS) as Assessed Radiographically by Blinded Independent Central Review (BICR) or by Histopathologic Confirmation of Suspected Disease Recurrence
Časové okno: Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by BICR or by histopathologic confirmation of suspected disease recurrence, will be presented.

Up to approximately 42 months
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Časové okno: Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.

Up to approximately 42 months
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Combined Positivity Score (CPS)-Determined Programmed Cell Death 1 Ligand 1 (PD-L1) Status
Časové okno: Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by CPS-determined PD-L1 status will be presented.

Up to approximately 54 months
Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Časové okno: Up to approximately 42 months

DFS is defined as the time from randomization to the first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first. The DFS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status, will be presented.

Up to approximately 42 months
Overall Survival (OS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease Recurrence by Tumor Mutation Burden (TMB) Status
Časové okno: Up to approximately 54 months

OS is defined as the time from randomization to death due to any cause. The OS as assessed radiographically by investigator or by histopathologic confirmation of suspected disease recurrence by tumor mutation burden (TMB) status will be presented.

Up to approximately 54 months
Number of Participants Who Experience One or More Adverse Events (AEs)
Časové okno: Up to approximately 54 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.

Up to approximately 54 months
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Časové okno: Up to approximately 52 weeks

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 52 weeks
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (QoL) Score
Časové okno: Baseline and up to approximately 54 months

The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Participant responses to questions 29 ("How would you rate your overall health during the past week?") and 30 ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented.

Baseline and up to approximately 54 months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Function Score
Časové okno: Baseline and up to approximately 54 months

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.

Baseline and up to approximately 54 months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Endometrial Cancer (EORTC QLQ-EN24) Score
Časové okno: Baseline and up to approximately 54 months

The EORTC-QLQ-EN24 is a 24-item questionnaire developed to be used in conjunction with the EORTC-QLQ-C30 to assess the quality of life of endometrial cancer patients. Participant responses are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in EORTC QLQ-E24 score will be presented.

Baseline and up to approximately 54 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Medical Director, Merck Sharp & Dohme LLC

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

10. ledna 2021

Primární dokončení (Odhadovaný)

20. listopadu 2026

Dokončení studie (Odhadovaný)

20. listopadu 2026

Termíny zápisu do studia

První předloženo

12. listopadu 2020

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2020

První zveřejněno (Aktuální)

18. listopadu 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit